Market Trends- Optimizing Post-Trial Access (PTA): Why the Pharmaceutical Industry is Streamlining PTA Processes
Time: 12:00 pm
day: Day 1
Details:
- Continuing the treatment after the closure of the clinical trial is more than a regulatory requirement- it’s a lifeline for patients who depend on investigational treatments. By streamlining PTA processes, pharmaceutical companies can deliver faster access to therapies, improve patient outcomes, and enhance operational efficiency
- Despite its importance, PTA remains underutilized. Many companies still rely on openlabel extensions and protocol extensions to ensure treatment continuity, often due to various challenges and limitations. However, in recent years, the industry has seen a growing shift toward broader adoption of PTA options
- In this session, we’ll explore why organizations of all sizes are increasingly considering PTA strategies and examine the key obstacles they face in implementing these programs effectively
